Top Markets
Coin of the day
Thalia Therapeutics Plc Thalia Therapeutics Plc

Thalia Therapeutics Plc

THAT
Ранг среди акций #40823
Thalia Therapeutics Plc, a specialized pharmaceutical company established in... Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Цена акции
$0.00918474
Рыночная капитализация
$76.44K
Изменение (1 день)
0.00%
Изменение (1 год)
38.04%
Страна
GB
Торговля Thalia Therapeutics Plc (THAT)

Категория

Коэффициент P/S для Thalia Therapeutics Plc (THAT)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Thalia Therapeutics Plc, текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Thalia Therapeutics Plc с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE